Literature DB >> 1898054

Identification of two calpastatin forms in rat skeletal muscle and their susceptibility to digestion by homologous calpains.

S Pontremoli1, E Melloni, P L Viotti, M Michetti, F Salamino, B L Horecker.   

Abstract

Two forms of calpastatin, differing in their specificity for the homologous calpain isozymes I and II, have been separated from rat skeletal muscle extracts and purified to homogeneity. Calpastatin I, the first form to elute in chromatography on DE32, is more effective against calpain I, while calpastatin II is more effective as an inhibitor of calpain II. Based on their molecular mass (approximately 105 kDa) both calpastatin forms belong to the high molecular mass class found in muscles of other animal species (Murachi, T., 1989, Biochem. Int. 18, 263-294). For calpain I, which is active with low (mu-M) concentrations of Ca2+, maximum inhibition with either calpastatin form was observed over a wide range of Ca2+ concentrations. With calpain II, which requires high (mM) concentrations of Ca2+ for activity, maximum inhibition required Ca2+ concentrations above 1 mM. Both calpastatin forms were found to be highly sensitive to degradation by calpain II, but almost completely resistant to degradation by calpain I. Degradation of calpastatin by calpain II is competitively inhibited by the addition of a calpain substrate. Isovaleryl carnitine (IVC), an intermediate product of L-leucine catabolism, previously demonstrated to be a potent and specific activator of rat skeletal muscle calpain II (Pontremoli, S., Melloni, E., Viotti, P. L., Michetti, M., Di Lisa, F., and Siliprandi, N., 1990. Biochem. Biophys. Res. Commun. 167, 373-380) greatly enhances the rate of degradation of calpastatins by calpain II. IVC, which decreases the Ca2+ requirement for maximal calpain II activity, also decreases the concentration of Ca2+ required for digestion of the inhibitor. For calpain II, regulation by either calpastatins may occur only in the presence of high [Ca2+].

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898054     DOI: 10.1016/0003-9861(91)90247-g

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  10 in total

1.  Changes in intracellular localization of calpastatin during calpain activation.

Authors:  R De Tullio; M Passalacqua; M Averna; F Salamino; E Melloni; S Pontremoli
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

2.  Changes in intracellular calpastatin localization are mediated by reversible phosphorylation.

Authors:  M Averna; R de Tullio; M Passalacqua; F Salamino; S Pontremoli; E Melloni
Journal:  Biochem J       Date:  2001-02-15       Impact factor: 3.857

3.  Increased calpain expression is associated with apoptosis in rat spinal cord injury: calpain inhibitor provides neuroprotection.

Authors:  S K Ray; D D Matzelle; G G Wilford; E L Hogan; N L Banik
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

4.  Calpain3 is expressed in a proteolitically active form in papillomavirus-associated urothelial tumors of the urinary bladder in cattle.

Authors:  Sante Roperto; Roberta De Tullio; Cinzia Raso; Roberto Stifanese; Valeria Russo; Marco Gaspari; Giuseppe Borzacchiello; Monica Averna; Orlando Paciello; Gianni Cuda; Franco Roperto
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

5.  Characterization of a new p94-like calpain form in human lymphocytes.

Authors:  Roberta De Tullio; Roberto Stifanese; Franca Salamino; Sandro Pontremoli; Edon Melloni
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

6.  Affinity labelling of the Ca(2+)-activated neutral proteinase (calpain) in intact human platelets.

Authors:  J Anagli; J Hagmann; E Shaw
Journal:  Biochem J       Date:  1993-01-01       Impact factor: 3.857

7.  Clinical severity of β-thalassaemia/Hb E disease is associated with differential activities of the calpain-calpastatin proteolytic system.

Authors:  Suriyan Sukati; Saovaros Svasti; Roberto Stifanese; Monica Averna; Nantika Panutdaporn; Tipparat Penglong; Edon Melloni; Suthat Fucharoen; Gerd Katzenmeier
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

8.  Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia.

Authors:  P Costelli; R De Tullio; F M Baccino; E Melloni
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

9.  Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia.

Authors:  Fabrizio Pin; Valerio G Minero; Fabio Penna; Maurizio Muscaritoli; Roberta De Tullio; Francesco M Baccino; Paola Costelli
Journal:  Front Physiol       Date:  2017-04-19       Impact factor: 4.566

10.  Role of calpain in apoptosis.

Authors:  Hamid Reza Momeni
Journal:  Cell J       Date:  2011-08-24       Impact factor: 2.479

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.